TY - JOUR
T1 - Paranasal sinus malignancies
T2 - An 18-year single institution experience
AU - Myers, Larry L.
AU - Nussenbaum, Brian
AU - Bradford, Carol R.
AU - Teknos, Theodoros N.
AU - Esclamado, Ramon M.
AU - Wolf, Gregory T.
PY - 2002/11/1
Y1 - 2002/11/1
N2 - Objectives: To characterize a single institution experience with management of paranasal sinus malignancies during an 18-year time period, report long-term survival rates, and identify prognostic factors. Study Design: Retrospective chart review. Methods: Studied were 141 patients treated for a paranasal sinus malignancy at a single institution from 1980 to 1997 with a minimum 3-year follow-up. Gender, age, TNM stage, anatomic site, pathology, treatment, and recurrence rates were reviewed. Multivariate analysis was performed to determine factors affecting survival. Results: The male to female ratio was 1.6:1, and the median patient age was 60 years. Most patients presented with T3/T4 or locally advanced disease (88%), NO status (96%), and MO status (96%). The maxillary sinus was the most commonly affected site (70%), followed by the ethmoid sinus (26%). The most common malignancy was squamous cell carcinoma (51%), followed by adenoid cystic carcinoma (12%) and adenocarcinoma (11%). Sixty-two percent of this study group underwent surgery as part of a multimodality curative treatment plan or alone as curative treatment. Eighteen patients (13%) had unresectable local disease and received non-surgical palliative treatment. Kaplan-Meier analysis revealed the 5-year and 10-year disease-specific survival was 52% and 35%, respectively. Multivariate analysis revealed T4 stage (P = .005), N-positive stage (P = .009), and M-positive stage (P = .018) negatively impacted survival. Seventy-two patients (51%) developed recurrent disease at a median time of 336 days after initial treatment. Conclusions: Most patients with paranasal sinus malignancies presented with locally advanced disease. Advanced T stage, regional, and distant metastasis are highly predictive of poor survival. Recurrence rate is high and typically occurs within the first year after treatment.
AB - Objectives: To characterize a single institution experience with management of paranasal sinus malignancies during an 18-year time period, report long-term survival rates, and identify prognostic factors. Study Design: Retrospective chart review. Methods: Studied were 141 patients treated for a paranasal sinus malignancy at a single institution from 1980 to 1997 with a minimum 3-year follow-up. Gender, age, TNM stage, anatomic site, pathology, treatment, and recurrence rates were reviewed. Multivariate analysis was performed to determine factors affecting survival. Results: The male to female ratio was 1.6:1, and the median patient age was 60 years. Most patients presented with T3/T4 or locally advanced disease (88%), NO status (96%), and MO status (96%). The maxillary sinus was the most commonly affected site (70%), followed by the ethmoid sinus (26%). The most common malignancy was squamous cell carcinoma (51%), followed by adenoid cystic carcinoma (12%) and adenocarcinoma (11%). Sixty-two percent of this study group underwent surgery as part of a multimodality curative treatment plan or alone as curative treatment. Eighteen patients (13%) had unresectable local disease and received non-surgical palliative treatment. Kaplan-Meier analysis revealed the 5-year and 10-year disease-specific survival was 52% and 35%, respectively. Multivariate analysis revealed T4 stage (P = .005), N-positive stage (P = .009), and M-positive stage (P = .018) negatively impacted survival. Seventy-two patients (51%) developed recurrent disease at a median time of 336 days after initial treatment. Conclusions: Most patients with paranasal sinus malignancies presented with locally advanced disease. Advanced T stage, regional, and distant metastasis are highly predictive of poor survival. Recurrence rate is high and typically occurs within the first year after treatment.
KW - Malignant neoplasms
KW - Paranasal sinus cancer
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0036843345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036843345&partnerID=8YFLogxK
U2 - 10.1097/00005537-200211000-00010
DO - 10.1097/00005537-200211000-00010
M3 - Article
C2 - 12439163
AN - SCOPUS:0036843345
SN - 0023-852X
VL - 112
SP - 1964
EP - 1969
JO - Laryngoscope
JF - Laryngoscope
IS - 11
ER -